Pembrolizumab

Quiénes somos

  • 5 de abril de 2022
    Estudio de la ventana de oportunidad en el cáncer colorrectal
  • 5 de abril de 2022
    A Study of ALX148 With Cetuximab and Pembrolizumab for Refractory Microsatellite Stable Metastatic Colorectal Cancer
  • 5 de abril de 2022
    Pembrolizumab e interleucina-12 recombinante en el tratamiento de pacientes con tumores sólidos
  • 5 de abril de 2022
    Chemotherapy and Immunotherapy as Treatment for MSS Metastatic Colorectal Cancer With High Immune Infiltrate
  • 5 de abril de 2022
    Study of Lenvatinib (MK-7902/E7080) in Combination With Pembrolizumab (MK-3475) Versus Standard of Care in Participants With Metastatic Colorectal Cancer (MK-7902-017/E7080-G000-325/LEAP-017)
  • 5 de abril de 2022
    Pembrolizumab After Chemotherapy in Treating Patients With Colorectal Cancer That Has Spread to the Liver and Who Are Undergoing Liver Surgery
  • 5 de abril de 2022
    Personalized Immunotherapy in Adults With Advanced Cancers Immunotherapy in Adults With Advanced Cancers
  • 5 de abril de 2022
    Regorafenib and Pembrolizumab in Treating Participants With Advanced or Metastatic Colorectal Cancer
  • 5 de abril de 2022
    Pembrolizumab y Olaparib en Cáncer Colorrectal Avanzado (CCR) Deficiente en Recombinación Homóloga (HRD).
  • 5 de abril de 2022
    Testing the PD-1 Antibody, MK3475, Given With Ziv-aflibercept in Patients With Advanced Cancer